TELA Bio, Inc.

NasdaqGM TELA

TELA Bio, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD -6.27 M

TELA Bio, Inc. Shareholders' Equity is USD -6.27 M for the quarter ending September 30, 2024, a -120.53% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

TELA Bio, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 30.55 M, a 31.12% change year over year.
TELA Bio, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 23.30 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGM: TELA

TELA Bio, Inc.

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway
Employees	227
Sector	Materials
Industries Plastics 3D Printing Automotive Parts Biotechnology Composite Materials Containers & Packaging Glass Medical Instruments

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key trends

Past 5 years